Doxorubicin Hydrochloride — Drug Intelligence | 104 EU Trials

Filter these 104 trials by condition, phase, country and more.

Open in Search →

104 Registered trials

54 Recruiting

40 Completed trials

73 Sponsors

24 Countries

Phase III

Phase II

Phase III: 53 Phase II/III: 4 Phase II: 32 Phase I/II: 7 Phase III/IV: 1 Phase IV: 6 Phase I (FiH): 1

Oversight events:

2 serious breaches 2 temporary halts 5 urgent safety measures 6 unexpected events 1 corrective measure across 10 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 9 Ovarian cancer 5 Fallopian tube cancer 4 Follicular lymphoma 4 Endometrial cancer recurrent 3 Ovarian epithelial cancer 3 Endometrial cancer 3 Hormone receptor positive breast cancer 3 Triple negative breast cancer 3 Follicle centre lymphoma follicular grade I II III 2 Hepatocellular carcinoma 2 Soft tissue sarcoma 2

Sponsors using this IMP

Merck Sharp & Dohme LLC 6 AbbVie Deutschland GmbH & Co. KG 4 Genmab A/S 4 Institut Bergonie 3 LYSARC 3 Unicancer 3 University Of Cologne 3 AstraZeneca AB 2 Celgene Corp. 2 Champalimaud Clinical Centre 2 European Organisation For Research And Treatment Of Cancer 2 Fondazione Italiana Linfomi Ets 2

All trials — page 3

104 total

A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan… Recruiting

2023-508227-13-00 Phase I (FiH) 1 country Exscientia AI Limited
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Phase IV 2 countries Lysarc
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: … Recruiting

2024-515981-14-00 Phase III 1 country Azienda Ospedaliera Universitaria Integrata Verona
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting

2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of … Recruiting

2024-518263-35-00 Phase II 1 country Hellenic Society Of Hematology
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ov… Recruiting

2024-515310-40-01 Phase II 1 country Asso De Recherche Cancers Gynecologiques
Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall Recruiting

2023-510185-27-00 Phase II 1 country Oslo University Hospital HF
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri… Recruiting

2024-516649-38-00 Phase III 4 countries Fondazione Policlinico Universitario Agostino Gemelli IRCCS
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting

2022-501456-28-00 Phase III 12 countries GPOH gGmbH
SIOP RANDOMET 2017 Recruiting

2023-508926-91-00 Phase III 10 countries GPOH gGmbH
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial) Recruiting

2024-515080-54-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting

2023-508101-24-00 Phase III 14 countries Universitaetsklinikum Muenster AöR
PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISS… Recruiting

2023-509489-39-00 Phase III 1 country Institut Bergonie
Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r… Recruiting

2024-514780-26-00 Phase II 1 country Unicancer
Paediatric Hepatic International Tumour Trial Recruiting

2024-516110-38-00 Phase III 10 countries The University Of Birmingham
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Phase III 7 countries Gilead Sciences Inc.
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 Phase III 17 countries Celgene Corp.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended

2022-501561-51-00 Phase II 1 country Institut Curie
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended

2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Phase III 9 countries Pharma Mar S.A.
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
Clinical trial to evaluate the effects of chemotherapy with anthracycline, after radiotherapy, in a group of pediatric and young adult patie… Ended

2024-519135-41-00 Phase II 1 country Azienda Ospedaliera Universitaria Meyer IRCCS

Showing 49–72 of 104 trials

← All drugs A–Z